(a) | by inserting, immediately after item (34) of paragraph 1, the following item:“(34A) | (2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide (also known as Lisdexamphetamine or Lisdexamfetamine) and its stereoisomers”; |
|
|
(b) | by inserting, immediately after item (120) of paragraph 1, the following item:“(120A) | 4-Phenyl-N-(2-phenylethyl)piperidin-4-yl acetate (also known as 1-Phenethyl-4-phenyl-4-piperidinol acetate or PEPAP)”; |
|
|
(c) | by inserting, immediately after item (8) of paragraph 7, the following items:“(8AA) | Cyclopropylfentanyl | (8AB) | 4-Fluorobutyrfentanyl (also known as para-Fluoro-butyrfentanyl or p-Fluoro-butyrfentanyl) | (8AC) | 2-Fluorofentanyl (also known as ortho-Fluorofentanyl) | (8AD) | 3-Fluorofentanyl (also known as meta-Fluorofentanyl) | (8AE) | 4-Fluorofentanyl (also known as para-Fluorofentanyl)”; |
|
|
(d) | by inserting, immediately after item (9) of paragraph 7, the following items:“(9A) | Methoxyacetylfentanyl | (9B) | 4-Methoxybutyrfentanyl (also known as para-Methoxy-butyrfentanyl or p-Methoxy-butyrylfentanyl)”; |
|
|
(e) | by deleting item (11) of paragraph 7; |
(f) | by deleting the word “N-Ethylpentylone” in item (1C) of paragraph 16 and substituting the words “1-(2H-1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) or N-Ethylpentylone or N-Ethylnorpentylone or Ephylone”; |
(g) | by deleting item (1) of paragraph 18 and substituting the following items: “(1) | N-(Adamant-1-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37) | (1AAA) | N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group”; |
|
|
(h) | by inserting, immediately after the words “also known as” in item (2BA) of paragraph 18, the words “N‑(1‑Amino‑3,3‑dimethyl‑1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]‑1H‑indazole‑3‑carboxamide or”; |
(i) | by inserting, immediately after item (10) of paragraph 18, the following item:“(10AA) | 3,4-Dichloromethylphenidate and its dichloro positional isomers in the phenyl ring (also known as 3,4‑DCMP)”; |
|
|
(j) | by inserting, immediately after item (20A) of paragraph 18, the following item:“(20AA) | 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as 5-Fluoro-cumyl-PICA) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group”; |
|
|
(k) | by deleting the word “MMB-FUBINACA” in item (28F) of paragraph 18 and substituting the words “Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate or MMB-FUBINACA or AMB-FUBINACA or FUB-AMB”; |
(l) | by inserting, immediately after the words “also known as” in item (31A) of paragraph 18, the words “1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide or”; |
(m) | by inserting, immediately after item (35) of paragraph 18, the following item:“(35A) | Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate (also known as 5-Fluoro-SDB-005) and its fluoro positional isomers in the pentyl group”; |
|
|
(n) | by inserting, immediately after item (36A) of paragraph 18, the following item:“(36AA) | Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (also known as SDB-005)”; and |
|
|
(o) | by deleting item (38AA) of paragraph 18. |